Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019
May 10 2019 - 4:01PM
Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company
leveraging its proprietary DNAbilize® antisense RNAi nanoparticle
technology to develop a portfolio of targeted nucleic acid cancer
drugs, today announced that it will host a live conference call and
audio webcast on Thursday, May 16, 2019 at 8:30 a.m. ET to report
financial results for the first quarter ended March 31, 2019 and to
provide a business overview.
To access the live conference call, please call (844) 815-4963
(domestic) or (210) 229-8838 (international) at least five minutes
prior to the start time and refer to conference ID 4956638. A live
audio webcast of the call will also be available on the
Presentations section of the Company’s website,
www.biopathholdings.com. An archived webcast will be available on
the Bio-Path website approximately two hours after the
event.
About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a
novel technology that has yielded a pipeline of RNAi nanoparticle
drugs that can be administered with a simple intravenous
transfusion. Bio-Path’s lead product candidate, prexigebersen
(BP1001, targeting the Grb2 protein), is in a Phase 2 study
for the treatment of blood cancers and in preclinical studies
for solid tumors. The Company is also developing BP1002, which
targets the Bcl-2 protein and is expected to be evaluated for
the treatment of lymphoma and solid tumors. In addition,
BP1003, a novel liposome incorporated STAT3
antisense oligodeoxynucleotide developed by Bio-Path as a
specific inhibitor of STAT3, is expected to enter Phase 1
studies in 2020.
For more information, please visit the Company's website at
http://www.biopathholdings.com.
Contact
Information:
Investors
Will O’ConnorStern Investor Relations
212-362-1200will@sternir.com
Doug Morris Investor Relations Bio-Path Holdings, Inc.
832-742-1369
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bio Path (NASDAQ:BPTH)
Historical Stock Chart
From Sep 2023 to Sep 2024